SCHEMBL6234919

SCHEMBL6234919

COc1cc(CC(=O)O)ccc1N(C(N)=O)c1ccccc1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.48
ALDH1A1 P00352 3/20 0.48
TSHR P16473 1/20 0.48
NFKB1 P19838 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA5A P35218 1/20 0.43
LMNA P02545 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NR3C1 P04150 1/20 0.42
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
SELL P14151 1/20 0.40
SELP P16109 1/20 0.40
KMT2A Q03164 1/20 0.40
BCHE P06276 2/20 0.39
ACHE P22303 2/20 0.39
PTGS1 P23219 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5155305 0.87 GAA (0.49) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6208255 0.86 NR3C1 (0.41) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL5152157 0.86 GAA (0.48) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6962762 0.86 GAA (0.48) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL5155259 0.86 ALDH1A1 (0.48) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL5273127 0.85 GAA (0.52) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL5152274 0.83 GAA (0.45) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6964628 0.82 GAA (0.46) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL7174167 0.79 KMT2A (0.41) GAAALDH1A1LMNAKMT2A
SCHEMBL6820924 0.77 AKR1B1 (0.41) GAATSHRLMNACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 GAA 1709/4885ALDH1A1 146/4885TSHR 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.